| Rinvoq (upadacitinib) / AbbVie |
NCT06446219: Efficacy and Safety Comparison of Upadacitinib and Vedolizumab in Second-line Treatment for Crohn's Disease |
|
|
| Completed | N/A | 172 | RoW | | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn Disease | 03/24 | 03/24 | | |
NCT06274996: Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease |
|
|
| Completed | N/A | 81 | RoW | Upadacitinib | Sixth Affiliated Hospital, Sun Yat-sen University | Inflammatory Bowel Diseases | 12/23 | 12/23 | | |
| Available | N/A | | NA | Upadacitinib, ABT-494, Rinvoq, C25-267 | AbbVie | Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis | | | | |
| Recruiting | N/A | 240 | Europe | Upadacitinib, Dupilumab | Technische Universität Dresden | Atopic Dermatitis | 12/25 | 12/25 | | |
UPWARDS, NCT04267536: An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis |
|
|
| Completed | N/A | 534 | Europe | | AbbVie | Rheumatoid Arthritis (RA) | 02/22 | 02/22 | | |
UPA-AGE, NCT06922331: Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis |
|
|
| Completed | N/A | 21 | RoW | Upadacitinib | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn's Disease (CD), Ulcerative Colitis (UC), Refractory Crohn's Disease, Refractory Ulcerative Colitis, Inflammatory Bowel Disease (IBD), Pediatric Crohn's Disease, Geriatric Ulcerative Colitis | 12/24 | 03/25 | | |
UPJOINT, NCT04758117: A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis |
|
|
| Completed | N/A | 394 | Europe, Canada | | AbbVie | Psoriatic Arthritis | 07/23 | 07/23 | | |
NCT06144567: Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis |
|
|
| Not yet recruiting | N/A | 19 | Europe | Upadacitinib, Rinvoq | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Hospital Universitario de Móstoles | Psoriatic Arthritis | 06/26 | 06/26 | | |
ERUDA, NCT05989932: Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis |
|
|
| Completed | N/A | 146 | Europe | Upadacitinib | Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse | Atopic Dermatitis | 04/24 | 04/24 | | |
| Recruiting | N/A | 174 | RoW | Upadacitinib | Xiang Gao | Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis | 12/28 | 12/28 | | |
ENDEAVOUR, NCT05170646: An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid Arthritis |
|
|
| Completed | N/A | 97 | Europe | | AbbVie | Rheumatoid Arthritis | 01/24 | 01/24 | | |
NCT06573944: IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study |
|
|
| Recruiting | N/A | 34 | RoW | | The Third Xiangya Hospital of Central South University | Crohn's Disease, Upadacitinib, Intestinal Ultrasound, Predictors | 06/25 | 09/25 | | |
NCT04340115: Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets |
|
|
| Completed | N/A | 4211 | Japan | | AbbVie | Rheumatoid Arthritis (RA) | 08/25 | 08/25 | | |
MARAJA, NCT04530305: Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor |
|
|
| Recruiting | N/A | 60 | Europe | Upadacitinib <15 MG [Rinvoq] | University Hospital, Montpellier | Rheumatoid Arthritis | 04/24 | 10/24 | | |
UPDATE, NCT05327920: An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice |
|
|
| Completed | N/A | 93 | Europe | | AbbVie | Rheumatoid Arthritis | 04/24 | 04/24 | | |
UPHOLD, NCT04497597: A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | N/A | 1532 | Europe, RoW | | AbbVie | Rheumatoid Arthritis (RA) | 05/24 | 05/24 | | |
ChiCTR2400080649: Clinical observations on the treatment of moderate-to-severe atopic dermatitis and its comorbidities with Upadacitinib |
|
|
| Not yet recruiting | N/A | 64 | | None | The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, National Natural Science Foundation of China(81972961) | Moderate to severe atopic dermatitis and its complications | | | | |
REACH-AD, NCT06421740: An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China |
|
|
| Recruiting | N/A | 1000 | RoW | | AbbVie | Atopic Dermatitis | 06/26 | 06/26 | | |
NCT06459297: Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease |
|
|
| Completed | N/A | 105 | RoW | | AbbVie | Ulcerative Colitis, Crohn's Disease | 12/25 | 12/25 | | |
| Recruiting | N/A | 150 | Europe | Upadacitinib, Rinvoq, ATC 200000041628 | Universidade do Porto, INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., Unidade de Farmacovigilância do Porto, Unidade Local de Saúde de São João, E.P.E., Unidade Local de Saúde de Santo António, E.P.E., Unidade Local de Saúde de Gaia/Espinho, E.P.E., RISE Health | Inflammatory Disease, Drug Side Effect, Drug Use, Adverse Drug Event, Adverse Drug Reaction, Safety Issues | 10/24 | 12/24 | | |
OPTIMA, NCT06630715: Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis. |
|
|
| Recruiting | N/A | 178 | Europe | Upadacitinib 15 MG [Rinvoq] | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | Rheumatoid Arthritis (RA, Psoriatic Arthritis (PsA | 12/25 | 12/25 | | |
| Recruiting | N/A | 150 | RoW | Tofacitinib, Baricitinib, Ruxolitinib, Upadacitinib, Abrocitinib, Ritlecitinib | Second Affiliated Hospital, School of Medicine, Zhejiang University | Alopecia Areata, Janus Kinase Inhibitors | 12/26 | 12/26 | | |
CAN UpTIMISE, NCT05394792: An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab |
|
|
| Completed | N/A | 111 | Canada | | AbbVie | Atopic Dermatitis | 08/24 | 08/24 | | |
NCT06503536: A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review |
|
|
| Completed | N/A | 150 | RoW | | AbbVie | Atopic Dermatitis (AD) | 10/24 | 10/24 | | |
NCT06581042: Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium |
|
|
| Recruiting | N/A | 280 | Europe | | AbbVie | Ulcerative Colitis, Crohn's Disease | 09/29 | 09/29 | | |
CLOSEUP, NCT04574492: A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | N/A | 413 | Canada | | AbbVie | Rheumatoid Arthritis (RA) | 07/24 | 07/24 | | |
NCT06016517: Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis |
|
|
| Not yet recruiting | N/A | 18 | US | Etanercept, Enbrel, Adalimumab, Humira, Upadacitinib, Rinvoq, Tocilizumab | Tufts Medical Center | Arthritis, Rheumatoid | 08/27 | 12/28 | | |
UP-RISING, NCT06712628: A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING |
|
|
| Recruiting | N/A | 678 | Europe | | AbbVie | Moderate to Severe Rheumatoid Arthritis | 12/28 | 12/28 | | |
UpSPINE, NCT05094128: A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting |
|
|
| Recruiting | N/A | 352 | Europe | Upadacitinib, RINVOQ | AbbVie | Axial Spondylarthritis (r-axSpA) | 06/26 | 06/26 | | |
| Recruiting | N/A | 75 | Canada | TNFi, Etanercept, Adalimumab, Golimumab, Certolizumab, Anti-IL6, Tocilizumab, Sarilumab, JAKi, Tofacitinib, Upadacitinib, Baricitinib | Marie Hudson, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal General Hospital, Lady Davis Institute | Rheumatoid Arthritis | 12/25 | 12/26 | | |
NCT06454461: Efficacy of Upadacitinib After NECS in Vitiligo |
|
|
| Recruiting | N/A | 60 | RoW | Upadacitinib 15 MG, NECS | Jilin University | Vitiligo | 06/26 | 06/29 | | |
| Recruiting | N/A | 10000 | RoW | Biologic or targeted synthetic DMARD, etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biosimilars, tofacitinib, baricitinib, upadacitinib | Seoul National University Hospital | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 12/29 | 06/30 | | |
ADMIRE, NCT05451316: A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib |
|
|
| Completed | N/A | 1 | Japan | | AbbVie | Atopic Dermatitis | 11/24 | 11/24 | | |
UPSTAND, NCT04846244: A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib |
|
|
| Completed | N/A | 708 | Europe, Canada, RoW | | AbbVie | Axial Spondylarthritis (axSpA) | 03/25 | 03/25 | | |
NCT06838845: An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) |
|
|
| Recruiting | N/A | 80 | RoW | | AbbVie | Ulcerative Colitis | 12/26 | 12/26 | | |
ChiCTR2400090334: Efficacy and Safety of Abrocitinib and Upadacitinib in the Treatment of Children (Aged Below 12) with Moderate to Severe Atopic Dermatitis: A Real World Study |
|
|
| Recruiting | N/A | 25 | | therapeutic agents: abrocitinib or upadacitinib | Guangzhou Dermatology Hospital; Guangzhou Dermatology Hospital, Project Fund | atopic dermatitis | | | | |
NCT07166315: Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor |
|
|
| Recruiting | N/A | 700 | Europe | observational study | Adelphi Real World | Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA) | 03/27 | 03/27 | | |
CROHNOS, NCT07073079: A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting |
|
|
| Recruiting | N/A | 250 | Europe | | AbbVie | Crohn's Disease | 12/27 | 12/27 | | |
AD-VISE, NCT05081557: A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis |
|
|
| Active, not recruiting | N/A | 873 | Europe, Canada, RoW | | AbbVie | Atopic Dermatitis | 10/26 | 10/26 | | |
NCT06095596: Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis |
|
|
| Recruiting | N/A | 334 | RoW | Upadacitinib, Upadacitinib treatment, Vedolizumab, Vedolizumab treatment | Sixth Affiliated Hospital, Sun Yat-sen University | Ulcerative Colitis (UC) | 10/25 | 10/26 | | |
NCT05791526: An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan |
|
|
| Completed | N/A | 308 | Japan | | AbbVie | Ulcerative Colitis | 12/25 | 12/25 | | |
NCT04541810: A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis |
|
|
| Recruiting | N/A | 3600 | RoW | | AbbVie | Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) | 12/25 | 12/25 | | |
SELECT AXIS RW, NCT05609643: Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan |
|
|
| Recruiting | N/A | 100 | Japan | | AbbVie | Ankylosing Spondylitis | 12/25 | 12/25 | | |
ChiCTR2500107737: Comparison of Efficacy and Mechanism Exploration of Dupilumab and Upadacitinib in Moderate-to-Severe Atopic Dermatitis with Facial and Scalp Lesions |
|
|
| Not yet recruiting | N/A | 24 | | Dupixent (dupilumab) (Sanofi/, France) for adults: an initial dose of 600 mg, followed by 300 mg every two weeks via subcutaneous injection; for children weighing between 15 kg and 30 kg, a single 300 mg injection every four weeks after the initial dose.; The therapeutic dose should be adjusted based on the patient’s condition and treatment response. The starting dose is 15 mg once daily, which can be increased to 30 mg once daily if necessary. | The Fourth Affiliated Hospital of Soochow University (Suzhou Dushuhu Hospital); The Fourth Affiliated Hospital of Soochow University (Suzhou Dushuhu Hospital), Epitope Validation and Precision Therapy Research on Atopic Dermatitis Subtyping, Key Laboratory of Dermatology, AYPYS2024 | Atopic Dermatitis | | | | |
NCT05029895: A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD) |
|
|
| Completed | N/A | 167 | Japan | | AbbVie | Atopic Dermatitis | 09/25 | 09/25 | | |
UPtimum-PsA, NCT05616871: An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis |
|
|
| Active, not recruiting | N/A | 450 | Europe | | AbbVie | Psoriatic Arthritis | 07/27 | 07/27 | | |
NCT05959083: Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis |
|
|
| Active, not recruiting | N/A | 200 | RoW | | AbbVie | Atopic Dermatitis (AD) | 06/26 | 06/26 | | |
ChiCTR2500109214: Clinical study of JAK inhibitors in the treatment of rosacea with erythematotelangiectatic rosacea |
|
|
| Not yet recruiting | N/A | 84 | | Tofacitinib 5mg, orally twice daily; after the 16th week, the dosage should be reduced to Tofacitinib 5mg, orally once daily.; Upadacitinib 15mg, orally once daily; after the 16th week, the dosage should be reduced to Upadacitinib 15mg, orally once every other day.; Carvedilol 5mg, orally twice daily; after the 16th week, the dosage should be reduced to Carvedilol 5mg, orally once daily. | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Company | Rosacea | | | | |
ChiCTR2500111016: A single-center retrospective clinical study on the efficacy and safety of upadacitinib in the treatment of inflammatory myopathy with positive anti-melanoma differentiation-associated gene 5 (MDA5) antibody |
|
|
| Not yet recruiting | N/A | 15 | | None | The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, Joint Program of Science and Technology Plan of Liaoning Province (Natural Science Foundation - General Project) | Inflammatory myopathy | | | | |
UP-TAINED, NCT05139836: A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting |
|
|
| Active, not recruiting | N/A | 634 | Europe | | AbbVie | Atopic Dermatitis | 09/27 | 09/27 | | |
NCT06023030: An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan |
|
|
| Recruiting | N/A | 240 | Japan | | AbbVie | Crohn's Disease | 11/26 | 11/26 | | |
ChiCTR2400088541: A single-center, pilot, open-label, single-arm study to evaluate the effectiveness of Upadacitinib in the treatment of refractory localized scleroderma |
|
|
| Not yet recruiting | N/A | 21 | | Upadacitinib in combination with traditional therapy (prednisone + methotrexate) | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Special Fund for Clinical Research of Zhongshan Hospital in 2023 | localized scleroderma | | | | |
UPDATE, NCT05669794: An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World |
|
|
| Active, not recruiting | N/A | 300 | Europe | | AbbVie | Atopic Dermatitis | 02/27 | 02/27 | | |
EUROPE, NCT05496348: Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis |
|
|
| Recruiting | N/A | 400 | Europe | | AbbVie | Ulcerative Colitis | 08/27 | 08/27 | | |
PROFUNDUS, NCT05494606: An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice |
|
|
| Active, not recruiting | N/A | 785 | Europe, Canada, RoW | | AbbVie | Ulcerative Colitis | 03/28 | 03/28 | | |
NCT03358693: Molecular Signatures in Inflammatory Skin Disease |
|
|
| Recruiting | N/A | 300 | Europe | Anti-TNF, Anti-IL12/23, Anti-IL17, Dupilumab, Anti-IL23, Baricitinib, Abrocitinib, Upadacitinib, Tralokinumab, Lebrikizumab, Nemolizumab | Prof. Dr. Stephan Weidinger | Atopic Dermatitis, Psoriasis | 12/28 | 12/29 | | |
UPlift, NCT05930275: Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. |
|
|
| Active, not recruiting | N/A | 1200 | Europe, Canada, Japan, RoW | | AbbVie | Crohn's Disease | 09/28 | 09/28 | | |
ChiCTR2500098001: A comparative study on the efficacy and safety of upadacitinib versus various biologic agents in patients with inflammatory bowel disease |
|
|
| Not yet recruiting | N/A | 600 | | | Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Self-finance | Inflammatory bowel disease, including ulcerative colitis and Crohn's disease | | | | |
ChiCTR2400085121: Efficacy of upadacitinib after autologous non-cultured epidermal cell suspension transplantation in vitiligo participants——a pilot, random, observer blinded, comparative study |
|
|
| Not yet recruiting | N/A | 60 | | upadacitinib combined with autologous non-cultured epidermal cell suspension transplantation; autologous non-cultured epidermal cell suspension transplantation | The first hospital of Jilin University; The first hospital of Jilin University, Clinical research funding of the first hospital of Jilin University | vitiligo | | | | |
